Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma. Zabransky DJ, Kartalia E, Lee JW, Leatherman JM, et al. Hepatology 2024 Dec 3. doi: 10.1097/HEP.0000000000001185.

Read + Share

Amedeo Smart

Independent Medical Education

Zabransky DJ, Kartalia E, Lee JW, Leatherman JM, et al. Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma. Hepatology 2024 Dec 3. doi: 10.1097/HEP.0000000000001185.
PMID: 39626209